Login / Signup

Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study.

Anne-Noelle FrixLiam G HeaneyBarbro DahlénFlorin MihaltanSvetlana SergejevaSanja Popović-GrleVratislav SedlakLauri A LehtimäkiArnaud BourdinStephanie KornEleftherios ZervasZsuzsanna CsomaDora LúðvíksdóttirMarcus W ButlerGiorgio Walter CanonicaIneta GrisleKristina BieksieneAnneke Ten BrinkePiotr KunaClaudia Chaves LoureiroNatalia M NenashevaZorica LazicSabina ŠkrgatDavid Ramos-BarbonJoerg LeuppiBilun GemiciogluApostolos BossiosCeleste M PorsbjergElisabeth H BelRatko DjukanovicRenaud Louis
Published in: ERJ open research (2022)
Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation.
Keyphrases
  • healthcare
  • end stage renal disease
  • single cell
  • chronic kidney disease
  • mental health
  • patient reported outcomes
  • patient reported